兴齐眼药(300573) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥536,140,697.03, representing a 53.24% increase compared to ¥349,876,258.51 in the same period last year[4] - Net profit attributable to shareholders surged to ¥145,895,323.80, marking a 319.86% increase from ¥34,748,964.87 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥136,016,935.16, up 285.96% from ¥35,240,962.27 in the previous year[4] - Basic and diluted earnings per share rose to ¥0.83, a 315.00% increase from ¥0.28 in the previous year[4] - Operating profit surged to ¥178,145,643.57, up 276.5% from ¥47,251,127.99 in the prior period[23] - Net profit for the current period was ¥145,895,323.80, representing a 320.5% increase from ¥34,748,964.87 in the previous period[24] Cash Flow and Assets - Operating cash flow net amount increased by 128.46% to ¥190,621,929.88, compared to ¥83,437,890.69 in the same period last year[11] - Cash flow from operating activities generated a net inflow of ¥190,621,929.88, up from ¥83,437,890.69 in the previous period[26] - The company reported a cash and cash equivalents balance of ¥497,873,804.05 at the end of the period, down from ¥567,852,344.79 at the end of the previous period[26] - The company's cash and cash equivalents increased to CNY 505,157,872.57 from CNY 370,121,251.48, representing a growth of about 36.3%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,296,666,978.89, an 8.15% increase from ¥2,123,503,158.46 at the end of the previous year[4] - The total current liabilities rose to CNY 481,344,705.37 from CNY 461,483,344.51, indicating an increase of approximately 4.0%[19] - The company's total equity increased to CNY 1,743,262,336.73 from CNY 1,593,168,346.52, showing a growth of around 9.43%[20] - The inventory balance as of March 31, 2025, was CNY 166,084,418.58, up from CNY 153,598,936.63, marking an increase of about 8.0%[18] - The company reported a decrease in accounts receivable from CNY 241,589,286.42 to CNY 238,364,258.79, a decline of approximately 1.0%[18] - The company reported a significant increase in accounts payable, which rose by 30.13% to ¥23,067,986.06, attributed to increased procurement[9] Research and Development - The company has made progress in drug development, with the drug Voriconazole eye drops achieving Phase I clinical research[16] - The company received a drug registration certificate for Tafluprost eye drops, indicating successful regulatory progress[16] - Research and development expenses increased to ¥47,072,206.09, up 23.5% from ¥38,068,318.45 in the prior period[23] Tax and Expenses - The company incurred tax expenses of ¥31,638,569.37, compared to ¥6,906,991.12 in the previous period, reflecting a significant increase[23] - Total operating costs rose to ¥367,431,795.47, an increase of 17.3% from ¥313,254,777.41 in the previous period[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 42,629[12] Government Support - The company received government subsidies amounting to ¥12,203,639.44, contributing to its non-recurring gains[5]